The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire
Executive Summary
Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.
You may also be interested in...
Aducanumab: Biogen Is The Latest Firm To Preempt A Negative EU Opinion On Approval
The EU marketing application for aducanumab is heading for a rejection for Alzheimer’s disease, according to a “negative trend vote” at the CHMP disclosed by the drug’s sponsors.
Aduhelm Looks Set For Rejection In Europe For Alzheimer's
The EMA’s likely rejection is no surprise for Biogen and Eisai, but adds to problems in the same week as Biogen’s R&D leader announced his departure.
Biogen: Aduhelm Price Is Part Of Alzheimer's ‘Evolution’
The company insists it will reconsider the price of Aduhelm if the market turns out to be larger than Biogen anticipates, but big price reductions for branded drugs are rare.